CATAPRES-TTS-3 Drug Patent Profile
✉ Email this page to a colleague
When do Catapres-tts-3 patents expire, and what generic alternatives are available?
Catapres-tts-3 is a drug marketed by Lavipharm and is included in one NDA.
The generic ingredient in CATAPRES-TTS-3 is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Catapres-tts-3
A generic version of CATAPRES-TTS-3 was approved as clonidine by AVEVA on August 18th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CATAPRES-TTS-3?
- What are the global sales for CATAPRES-TTS-3?
- What is Average Wholesale Price for CATAPRES-TTS-3?
Summary for CATAPRES-TTS-3
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Clinical Trials: | 19 |
Patent Applications: | 4,359 |
DailyMed Link: | CATAPRES-TTS-3 at DailyMed |
Recent Clinical Trials for CATAPRES-TTS-3
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rigshospitalet, Denmark | Phase 2/Phase 3 |
Deventer Ziekenhuis | Phase 3 |
Queen's University, Belfast | Phase 3 |
Pharmacology for CATAPRES-TTS-3
Drug Class | Central alpha-2 Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha2-Agonists |
US Patents and Regulatory Information for CATAPRES-TTS-3
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CATAPRES-TTS-3
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CATAPRES-TTS-3
See the table below for patents covering CATAPRES-TTS-3 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Romania | 75336 | ⤷ Sign Up | |
Denmark | 117000 | ⤷ Sign Up | |
Sweden | 353721 | ⤷ Sign Up | |
Australia | 2846277 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |